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Background: Brain tumors in the first year of life are rare and their management remains 
challenging. 
Objective: To report on the contemporary management of brain tumors in infants with reference 
to previous series from our institution. 
Methods: Retrospective cohort study design. Electronic/paper case note review of all brain 
tumors diagnosed at our institution in children aged <1y since the publication of our previous 
series. 
Results: 98 patients were seen. The most common presentations were with vomiting and 
macrocrania, at a median age of 184 days. 62% of tumors were supratentorial. 91 patients 
underwent 230 procedures; 7 patients had no surgery. 118 operations were directly on brain 
tumors (biopsy 37, subtotal resection 47, gross total resection 34). 91 CSF diversions, 9 
endoscopic procedures, and 13 pre-operative embolizations were performed. Operative mortality 
was 4.4%. Tumor types in order of frequency were choroid plexus papillomas(CPP;17), 
primitive neuroectodermal tumor(PNET;12), atypical teratoid/rhabdoid tumor(ATRT;10), high 
grade glioma (HGG;9), optic glioma(9), ependymoma(8), low grade glioma(LGG;6), pilocytic 
astrocytoma(6), choroid plexus carcinoma(5) and teratoma(5), with 11 miscellaneous tumors. 
Survival was 93% at 1m(91/98), 64% at 1y(61/95), 44% at 5y(32/73), 28% at 10y(16/58). No 
patients with CPP or LGG died. Five-year survival rates were lowest for anaplastic 
ependymoma, PNET and ATRT. 77% of children reaching school age were in mainstream 
schooling. 
Conclusion: Overall survival from neonatal brain tumors remains similar to previous series; 
analysis of tumor subtypes reveals improvements for CPP and gliomas. Despite increasing 
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Introduction 
Intracranial tumors are the most common solid neoplasm of childhood. They are, however, rare 
in infants, where they account for only 0.5-1.9% of all pediatric central nervous system (CNS) 
tumors1. The management of this patient group is complex, due to a combination of histological 
heterogeneity, surgical and anesthetic challenges, and the deleterious effects of adjuvant 
chemotherapy and radiotherapy to the developing brain. Many series have previously reported 
poor survival, with 5-year survival rates between 21 and 81%2–9. Due to their rarity, much of the 
literature about infant brain tumors consists of limited surgical series, individual case reports and 
reviews. Here, we report the results of a third iteration of a consecutive series from a single 
institution, extending back over more than sixty years, and comprising the largest continuous 
case group in the literature3,10; the principal features of each study are summarized in Table 1. 
Our objective is to characterize the contemporary management of brain tumors in infants (aged 




Eligible participants were all children below one year of age diagnosed with brain tumors at our 
center, since the time of publication of this institution’s second cohort3 (i.e. from April 1997 to 
January 2014). Prospectively maintained databases were retrospectively interrogated to yield 
data on demographics, presentation, radiology, surgical techniques, adjuvant therapies, 
pathology, and survival. Patients were routinely followed up in neuro-oncology multidisciplinary 
team meetings and clinics. Our institution does not require additional patient consent or ethical 
approval for retrospective audits of this nature. A small proportion of patients from early in the 
cohort were lost to follow up due to emigration, but no missing data was encountered otherwise. 
Histopathological samples were analyzed by a team of specialist pediatric neuropathologists. 
Descriptive statistical analysis, Kaplan-Meier survival curves, and Breslow and Log Rank tests 
applied to these were performed with IBM SPSS Statistics (IBM, Armonk, New York). A 





Demography and clinical presentation 
98 patients presented during the study period; 55 were male. An average of 5.4 cases were 
referred per year, compared to 3.4 per year in our first series. The age at presentation ranged 
from day 1 of life to 354 days, with a median of 184 days. A mean of 8.2 patients presented in 
each month of age (range 3-14). The mean duration of symptoms prior to presentation was 49 
days. The most common presenting symptom was vomiting, followed by increased head 
circumference. The most common clinical signs on presentation were related to increased head 
circumference and hydrocephalus (see Figure 1). 
 
Imaging 
Multiple imaging modalities were used to investigate this group of patients. 94 patients (96%) 
had a magnetic resonance (MR) scan, 56 patients (57%) had a computed tomography (CT) scan, 
and 10 patients (10%) underwent cranial ultrasound (US). 52 patients (53%) had both MRI and 
CT. None of the patients had pre-operative diagnostic digital subtraction angiography or skull 
radiography. In one patient the lesion was diagnosed in the antenatal period by US. 
 
Neurosurgical procedures 
91 patients underwent a total of 230 surgical procedures, with 65 patients having more than one 
procedure (see Figure 2). Seven patients had no surgery: 4 had a radiological diagnosis of a low-
grade lesion (3 optic pathway gliomas, 1 low grade glioma); 1 child died pre-operatively; 1 child 
had surgery elsewhere and another was referred for palliative care for a very large tumor that was 
deemed inoperable. 
 
Median post-operative stay in hospital on index admission was 19 days (range 1 to 86 days). 85 
patients underwent 118 surgical procedures directly on brain tumors. Extent of resection, as 
judged by the operating surgeon and post-operative imaging, was biopsy in 37, subtotal resection 
in 47, and gross total resection in 34 operations. Safe maximal resection was attempted in all 
cases. A total of 89 cerebrospinal fluid (CSF) diversion procedures were performed (57 
ventriculoperitoneal shunt (VPS) procedures and 32 external ventricular drains (EVDs)) on 54 
patients. 2 ventricular access devices were implanted. 
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Endoscopic procedures were performed on 9 patients during the study period. Of these, 7 
patients underwent endoscopic third ventriculostomy (ETV) for obstructive hydrocephalus. 
Following the publication of a validated ETV success scoring system in 2009, these criteria were 
incorporated in the decision-making process11. 3 patients underwent septostomy; and 5 
underwent endoscopic biopsy (none of the patients undergoing endoscopic biopsy had a separate 
biopsy procedure). These endoscopic procedures were performed in combination or alone, and in 
all but one patient included an ETV or septostomy/fenestration. 3 of 8 children who had primary 
endoscopic management of hydrocephalus later underwent VPS procedures. 
 
Five patients underwent operative management but did not have a procedure on the tumor: 3 
underwent primary VPS procedures, 1 had an EVD later converted to a VPS, and 1 had a 
successful ETV performed. Only one of these children went on to have chemotherapy. Twelve 
patients, all with choroid plexus tumors, underwent 13 pre-operative tumor embolization 
procedures (see Figure 3 for an illustrative case). 
 
There were 4 peri-operative deaths (with 3 of these occurring in the first 7 years of the series), 
giving an overall operative mortality of 4.4%, a reduction compared to our previous cohorts’ 
figures of 7.6%3 and 30%10. All of these occurred within 30 days of surgery, but only in two 
cases was this due to unexpected complications of surgical procedures on the tumor (1 due to 
blood loss during tumor surgery, 1 contralateral intracerebral haemorrhage following biopsy). 
The remaining two post-operative deaths occurred in controlled circumstances in a palliative 
setting, with treatment limiting decisions made due to poor prognosis.  
 
Tumor pathology 
61 tumors were supratentorial, 36 infratentorial; 1 tumor extended into both compartments. In 86 
patients, a definitive histological diagnosis was made. In 83 patients this was achieved through 
the first surgical procedure on the tumor, and in 3 at post-mortem examination. Those without 
histology were diagnosed on clinical and radiological grounds. The different tumor types seen in 
this cohort are shown in Figure 4. Histological diagnoses in the ‘other’ category were cavernous 
angioma, craniopharyngioma, ganglioglioma, primary neuroepithelial tumor, angiosarcoma, 
ETANTR (embryonal tumor with abundant neuropil and true rosettes), melanocytic 
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neuroectodermal tumor of infancy and two unknown entities. Histological diagnoses in the 
miscellaneous glioma group were desmoplastic infantile astrocytoma and a non-specific glioma. 
 
Adjuvant therapy 
45 patients received adjuvant chemotherapy as part of their management. 1 patient underwent 
neo-adjuvant chemotherapy prior to any surgical treatment (which was a biopsy of a pilocytic 
astrocytoma). 11 patients received adjuvant radiotherapy. Four patients were given primary 
radiotherapy at a mean age of 13.8 months (range 12-15 months); all patients had PNETs. Seven 
patients underwent radiotherapy at tumor recurrence at a mean age of 42.4 months (range 18-78 
months), for a variety of tumors (ATRT, ganglioglioma, ependymoma, 2 anaplastic 
ependymoma, 2 glioma). No patients received radiotherapy under the age of 1 year. 
 
Survival 
Overall, 42 patients died during the study period, with the worst prognoses conferred by 
diagnosis of anaplastic ependymoma and PNET (5-year survival rate 0% for both diagnoses). 
None of the patients with choroid plexus papilloma (17) or histologically proven low-grade 
glioma (6) died during the study period. Mean overall follow up of survivors was 6.74 years 
(S.D. 4.60 years). Table 2 shows interval survival rates for all patients in the cohort. 
 
A Kaplan Meier survival curve for all patients treated surgically in the current series is shown in 
Figure 5, alongside the curve for our previous institutional series. A Breslow (generalised 
Wilcoxon) test did not show any significant difference between these distributions (2 statistic 
0.072, p = .79). The resolution of the data from the first published institutional series10 was 
insufficient to generative a similar survival curve; in this study the cumulative average survival 
was 27 months for the whole group, and 37 months for those infants who underwent surgery10. 
Survival rates stratified by tumor type are shown in Table 3. Kaplan-Meier survival curves 
generated from these data are shown in Figure 6. A non-parametric Log Rank (Mantel-Cox) test 
was applied to the differential survival curves, indicating a significant difference in survival 




Data on educational status was collected as an indicator of quality of life in those patients 
surviving to school age. 46 patients survived to school age and follow up data were available for 
39 patients (5 patients emigrated, 2 patients lost to follow up). 30 children (77%) were in 
mainstream schooling, of whom 10 (26%) required educational assistance; the remaining 9 
(23%) were in a special school. None of the patients requiring special schooling streams had 
undergone radiotherapy as part of their treatment protocol. Of the 20 children in unassisted 




All patients were managed within the pediatric neuro-oncology multidisciplinary group, which 
includes neurosurgeons, neuroradiologists, neuropathologists, oncologists, allied health 
professionals and nurse specialists. In addition, 47% of patients benefited from formal 
consultation from one or more allied medical specialities (ophthalmology (23%), endocrinology 
(11%), palliative care (6%), neurology (4%), pediatric intensive care services (4%) and 




The surgical management of brain tumors in infants remains challenging, and survival rates for 
many tumors remain low4,6,7,12,13. The results of the third iteration of this single centre cohort 
presented here show 5-year overall survival rates concordant with those reported in the 
literature5, but with significant variation in survival rates for different tumors14,15. 
 
Our series demonstrates a significant heterogeneity to the modes of presentation within this 
patient group (see Figure 1). However, in keeping with other case series12,13,16,17, the most 
common clinical sign on presentation was macrocrania. Vomiting was the most common 
symptom at presentation, with a reduction seen in more advanced neurological signs (such as 
papilloedema, nystagmus and focal neurological deficits) compared to our previous cohorts3,10. 
Improved infant surveillance in the neonatal period may underlie this finding, although the 
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duration of symptoms remains in the range of seven weeks, similar to previously3, due to the 
often non-specific nature of symptoms in this age group.  
 
Almost all patients (96%) underwent MR imaging. Although our results show a declining trend 
in its use, CT scanning is still commonly employed in primary hospitals as a first-line diagnostic 
tool, and 53% of patients had both CT and MR. In only one patient was diagnosis made 
prenatally. However, the increasing availability of advanced antenatal imaging techniques, 
particularly foetal MRI, may allow earlier diagnosis, safer parturition, and better surgical 
planning in the near future. 
 
In contrast to our previous cohort, where 25% of patients underwent diagnostic cerebral 
angiography3, this technique was not employed as a purely diagnostic test in any of the patients 
in this cohort. The only indication for pre-operative angiography was as an interventional 
procedure for patients where imaging was consistent with choroid plexus neoplasms. Twelve 
patients subsequently underwent embolization procedures, which have been shown to reduce 
perioperative blood loss and increase gross total resection rate18. 
 
The operative data from the current series indicate an increasing trend towards operative 
intervention compared to previous series. 66% of patients managed surgically underwent more 
than one procedure. This is partly explained by a preference in our unit to consider staged 
procedures; 23 children in this series underwent more than one tumor operation. This rise in 
operative intervention was not associated with an increase in surgical mortality; in fact, overall 
surgical mortality has declined in our current series, due to improvements in both surgical and 
anaesthetic safe practice. Gross total resection was achieved in 29% of the procedures performed 
directly on brain tumors, a similar figure to that noted in a recent retrospective report19. Our 
series also underlines the increasing use of endoscopy, undertaken in 9 infants, which has been 
shown to be safe, with low incidence of adverse events, in this patient population20. This allowed 
effective management of hydrocephalus and tumor biopsy (see Figure 2). 
 
In contrast to intracranial tumors in later childhood, infant brain tumors occur more commonly in 
the supratentorial space21, as shown in 62% of our patients. As molecular profiling of brain 
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tumors assumes greater relevance, there is an increasing value to obtaining tissue for definitive 
diagnosis, particularly in cases where no surgical treatment is to be recommended. In the current 
series, this was achieved in 88% of cases (compared to 78% previously3). Large database15 and 
literature22 reviews indicate that gliomas are the most common histological tumor type in this 
patient group, although  smaller, retrospective surgical series have not always been consistent 
with this 16,23,24. In this large series, there is a greater number of choroid plexus neoplasms (22% 
of tumors) compared with other series3,10,12,22. Our overall survival rates for these tumors of 95% 
compare reasonably well to those reported in the wider literature of around 73%12. 
 
The incidence of low grade glioma in this cohort (23 of 98 patients) was identical to that noted in 
a previous literature review22. The three-year observed survival of infants with low grade 
gliomas in a large review of the Surveillance, Epidemiology and End Results (SEER) database15 
was 85.6%, a figure which tallies with our 1-year and 5-year survival rates of 95% and 79% 
respectively. High-grade gliomas had a 3-year survival of 52.1%15, also similar to the 50% 1- 
and 5-year survival observed in our patients; this was an improvement upon our previous series 
result of 44%3. See Figure 7 for an illustrative case of this pathology. Other reports25 also 
indicate similar survival rates of high grade glioma in infants, which are better than those of 
older children and adults. These pathology-specific conclusions are however inherently limited 
in their robustness by the relatively small sample size compared to larger database studies. 
 
Compared with the previous series, we describe marginally fewer diagnoses of PNET (12% 
compared with 17%3), with a corresponding increase in the diagnosis of ATRT, a clinical entity 
only described within the last thirty years26, which shares histopathological characteristics with 
PNET and was previously misclassified as such. See Figure 8 for an illustrative case of this 
pathology. Both tumors have a poor prognosis in infants. At 1 year, survival of ATRTs and 
PNETs was 11% and 33% respectively, corroborating evidence from the SEER database15 that 
these tumors are amongst the most aggressive and difficult to manage in this age group. 
 
Comparison of Kaplan-Meier survival curves of surgically treated patients in the current series 
with those of our previous series3 (Figure 4) appears to show marginally worse survival of 
patients at early time points, but superior overall survival at later time points. We note, however, 
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that the Breslow test statistic showed no significant difference between the two distributions. 
This apparent difference may be partly explained by the high number of successfully treated 
choroid plexus papillomas seen in the present series, as well as improved anaesthetic, surgical 
and oncological techniques in the current cohort.  
 
As with any retrospective cohort, limitations in the validity of the data exist due to the nature of 
data collection, although this was mitigated by interrogating a well-maintained prospective 
database of all brain tumor patients at our institution. Misclassification bias at chart review was 
limited by adherence to a rigorous pre-designed abstraction format. Selection bias was 
eliminated by including all patients under age one with a newly diagnosed brain tumor, which 
included patients from a wide referral network with an ethnically diverse population, making the 
results externally generalizable. Indeed, most brain tumors in infants are managed in highly 
specialised paediatric neurosurgical units accepting national and international referrals. 
 
In recent years, concerns regarding the long-term outcomes of children with intracranial tumors 
in the first year of life have been addressed, with an increasing emphasis on quality of life in 
survivors. There are a wide range of medical, psychosocial and economic27 sequelae of brain 
tumor treatment in infancy, as well as a cumulative mortality at 30 years of 25%28. The quality of 
life outcomes measured in this cohort of patients, in the form of educational ability and stream, 
are similar to that of our previous cohort, although too unrefined to characterise nuances of 
cognitive outcome. No patients requiring assisted or special schooling streams later in life had 
undergone radiotherapy as part of their treatment protocol in infancy, so the results from this 
limited series unfortunately cannot address the question of the functional consequences of focal 
radiation therapy in infants. In addition, the presence of other disabilities such as epilepsy, shown 
to have a prevalence of up to 25% in a historical International Society of Pediatric Neurosurgery 
survey21, have not been recorded here. Long-term data on functional outcome from neurosurgery 
for brain tumors in the first year of life are beginning to emerge29, however, with favourable 
results; future studies should aim to incorporate neurocognitive and developmental outcomes 
into their reporting. 
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With the broadening of the multidisciplinary team remit in recent years has come the practise of 
shared care between neuro-oncology and neurosurgical teams. Other specialists may advocate 
active treatment of cases that to the neurosurgical eye may appear futile, and only likely to 
prolong the family’s suffering. Where the clinical course for these patients is complicated by 
serious sequelae, and overall prospects of survival are poor, it is not unreasonable to ask whether 
some of these children should be treated at all. This is a difficult issue requiring sensitive 




Despite advances in surgery and adjuvant therapy, overall survival from neonatal brain tumors 
remains poor and not significantly improved over the last thirty years. However, analysis of 
individual tumor types reveals improvements particularly with respect to choroid plexus tumors 
and gliomas, notwithstanding the inherent limitations of this single-center series. Despite 
increasing operative intervention, surgical mortality continues to decline. Endoscopic and 
interventional radiology procedures have made a significant contribution to the management of 
this group of patients. Future studies addressing long-term quality of life and neurocognitive 
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Figure 1. Bar chart showing incidence of clinical symptoms and signs on presentation (in %) in 
the current series along with comparative figures from previous institutional cohorts. 
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 Jooma et al 10 Kane et al 3 Current series 
Recruitment period 1953 – 1981 1982 – 1996 1997 – 2014 
Size of cohort 100 75 98 
Mean duration of symptoms (weeks) up to 14 6.5 7 
CT scan (%) 14 88 57 
MRI scan (%) 0 47 96 
Patients undergoing tumour surgery (%) 68 88 87 
Gross total resection (%) 28 33 29 
Subtotal resection or biopsy (%) 72 44 71 
Operative mortality (%) 33 7.6 4.4 
Radiotherapy (as part of initial treatment) (%) 39 17 4 
Chemotherapy (as part of initial treatment) (%) 0 34 45 
 





Figure 2. Flowchart showing nature of neurosurgical operations performed on the patient cohort. 
The table shows operative data across the three institutional series. STR, subtotal resection; 
GTR, gross total resection; VPS, ventriculoperitoneal shunt; EVD, external ventricular drain; 





Figure 3. Eleven month-old girl with a large left hemispheric choroid plexus carcinoma. The 
patient underwent pre-operative embolization followed by staged resection, involving three 
craniotomies over four weeks. Despite tumor embolization, intra-operative blood loss remained a 
significant problem, and limited the first and second procedures. Following surgical recovery she 
underwent 6 courses of Cyclophosphamide, Etoposide and Vincristine chemotherapy over 6 
months. A, pre-operative MR scan showing large enhancing left hemispheric lesion. B, pre-
operative digital subtraction angiogram, lateral view of left vertebral artery contrast injection 
showing glue embolization of tumor-supplying left posterior choroidal artery (black arrow). C, 
contrast-enhanced axial CT scan after first craniotomy and resection. D, MR scan after second 
craniotomy showing significant reduction in tumor volume. E, MR scan after third craniotomy 
with gross total resection of tumor; this was followed by chemotherapy. F, 2-year follow up MR 




Figure 4. Incidence of tumor types seen in patient cohort. PNET, primitive neuroectodermal 
tumor (of which 4 were supratentorial); ATRT, atypical rhabdoid/teratoid tumor; HGG, high 




Survival at  
1 month 93% (91/98) 
6 months 71% (67/95) 
1 year 64% (61/95) 
3 years 55% (47/86) 
5 years 44% (32/73) 
10 years 28% (16/58) 
 
 




Figure 5. Kaplan-Meier survival curves for all patients treated surgically in the current series 
(solid line), and for our previous institutional series (dashed line). Breslow (generalised 
Wilcoxon) 2 statistic 0.072, p = .79. 
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Tumour type 1 month 1 year 5 year 10 year 
CPP 17/17 (100%) 17/17 (100%) 17/17 (100%) 17/17 (100%) 
LGG 22/22 (100%) 21/22 (95%) 11/14 (79%) 7/10 (70%) 
CPC 5/5 (100%) 3/4 (75%) 2/3 (67%) 2/3 (67%) 
     
HGG 7/9 (78%) 4/8 (50%) 4/8 (50%) 1/5 (20%) 
     
PNET 11/12 (92%) 4/12 (33%) 0/10 (0%) 0/8 (0%) 
Teratomas 5/5 (100%) 2/5 (40%) 0/3 (0%) 0/3 (0%) 
ATRT 7/10 (70%) 1/9 (11%) 1/9 (11%) 0/7 (0%) 
Ependymomas 6/8 (75%) 4/8 (50%) 1/8 (12.5%) 1/8 (12.5%) 
 
 
Table 3. Survival rates at 1 month, 1, 5 and 10 years for specific tumor types. LGG group 
includes optic gliomas, PXAs, pilocytic astrocytomas, true low grade gliomas and 2 
miscellaneous non-malignant gliomas. CPP, choroid plexus papilloma; LGG, low grade gliomas; 
CPC, choroid plexus papilloma; HGG, high grade glioma; PNET, primitive neuroectodermal 





Figure 6. Kaplan-Meier curve showing differential survival of 4 most numerous tumors seen in 
the current cohort; 2 statistic 24.78, p < .001. CPP, choroid plexus papilloma; HGG, high grade 






Figure 7. Infant girl with large left frontal high grade glioma diagnosed on day 1 of life. The 
patient was initially managed surgically with an open biopsy followed by gross total resection. 
She then underwent 2 cycles of chemotherapy on a modified HIT-SKK protocol30 involving 
cyclophosphamide, vincristine, carboplatin, etoposide and methotrexate. A, pre-operative axial 
T2-weighted MRI. B, post-biopsy scan with some relief of mass effect. C, post-resection scan, 
consistent with gross total resection. D, 2 year follow up scan showing no tumor recurrence. All 






Figure 8. Ten month old girl with infratentorial heterogeneous non-enhancing atypical 
teratoid/rhabdoid tumor. Following gross total resection, she underwent chemotherapy according 
to a published protocol31 involving Vincristine, Cyclophosphamide, Actinomycin, with 
subsequent high dose Carboplatin and Thiotepa and peripheral stem cell rescue. A, pre-operative 
scan. B, post-operative scan demonstrating gross total resection. C, surveillance scan at three 
years. All scans sagittal T1-weighted post-Gadolinium MRI. 
